Erasca Inc.

ERAS

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RTW Investments Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 146,651Value: $546K

**Signal Note: RTW Investments Initiates ERAS Position** RTW's entry into Erasca suggests confidence in the company's pipeline of allosteric MEK inhibitors for RAS-driven cancers, where differentiated pharmacology could address resistance mechanisms. The $546K position size is modest relative to RTW's typical allocations, warranting monitoring of whether this scales ahead of near-term catalysts (likely clinical data readouts in 2024-2025 for EOS-2101 across solid tumors and hematologic malignancies).

Rock Springs CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX2 funds OMDA2 funds NGNE2 funds PEN2 funds ACAD2 funds ALKS2 funds PTCT2 funds ZLAB

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Rock Springs Capital Initiates ERAS Position Rock Springs' $3.5M entry into Erasca suggests conviction in the company's RAS pathway inhibitor portfolio, particularly ERS-209 in KRAS-mutant cancers where clinical readouts are expected through 2024-2025. The healthcare specialist's initiation timing may reflect positioning ahead of upcoming data catalysts, though the concentrated fund's thesis warrants monitoring given ERAS's clinical-stage risk profile and competitive KRAS inhibitor landscape.